바이오시밀러 시장(2026-2030년)

The global biosimilars market is forecasted to grow by USD 38171.7 mn during 2025-2030, accelerating at a CAGR of 13.3% during the forecast period. The report on the global biosimilars market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing patent expirations and intensifying focus on cost-effectiveness, rising global incidence of chronic and autoimmune diseases, technological advancements in progress in biomanufacturing.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's global biosimilars market is segmented as below:

By Product Type

• Monoclonal antibodies
• Insulin
• Human growth hormone
• Others

By Application

• Oncology and hematology
• Endocrinology
• Immunology
• Nephrology

By Manufacturing Type

• In-house manufacturing
• Contract manufacturing

Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
• Asia
• Rest of World (ROW)
• Rest of World (ROW)

This study identifies the strategic shift towards interchangeability and pursuit of bio betters as one of the prime reasons driving the global biosimilars market growth during the next few years. Also, expansion into novel therapeutic areas and increased focus on emerging markets and embracing vertical integration and advanced manufacturing technologies will lead to sizable demand in the market.

The report on the global biosimilars market covers the following areas:

• Global biosimilars market sizing
• Global biosimilars market forecast
• Global biosimilars market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global biosimilars market vendors that include Abbott Laboratories, Biocon Ltd., Dr. Reddys Laboratories Ltd., Fresenius Kabi AG, Intas Pharmaceuticals Ltd., Kashiv Biosciences LLC, Mabxience Holding S.L., NeuClone Pty Ltd., Organon and Co., Pfizer Inc., Reliance Life Sciences Pvt. Ltd., Samsung Bioepis Co. Ltd., Sandoz Group AG, STADA Arzneimittel AG, Teva Pharmaceutical Ltd., Viatris Inc., Zentiva Group, Zydus Lifesciences Ltd.. Also, the global biosimilars market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

• 1.1 Market overview
  • Executive Summary - Chart on Market Overview
  • Executive Summary - Data Table on Market Overview
  • Executive Summary - Chart on Global Market Characteristics
  • Executive Summary - Chart on Market by Geography
  • Executive Summary - Chart on Market Segmentation by Product Type
  • Executive Summary - Chart on Market Segmentation by Application
  • Executive Summary - Chart on Market Segmentation by Manufacturing Type
  • Executive Summary - Chart on Incremental Growth
  • Executive Summary - Data Table on Incremental Growth
  • Executive Summary - Chart on Company Market Positioning

2 Technavio Analysis

• 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 2.2 Criticality of inputs and Factors of differentiation
• 2.3 Factors of disruption
• 2.4 Impact of drivers and challenges

3 Market Landscape

• 3.1 Market ecosystem
• 3.2 Market characteristics
• 3.3 Value chain analysis

4 Market Sizing

• 4.1 Market definition
• 4.2 Market segment analysis
  • Market segments
• 4.3 Market size 2025
• 4.4 Market outlook: Forecast for 2025-2030

5 Historic Market Size

• 5.1 Global Biosimilars Market 2020 - 2024
  • Historic Market Size - Data Table on Global Biosimilars Market 2020 - 2024 ($ million)
• 5.2 Product Type segment analysis 2020 - 2024
  • Historic Market Size - Product Type Segment 2020 - 2024 ($ million)
• 5.3 Application segment analysis 2020 - 2024
  • Historic Market Size - Application Segment 2020 - 2024 ($ million)
• 5.4 Manufacturing Type segment analysis 2020 - 2024
  • Historic Market Size - Manufacturing Type Segment 2020 - 2024 ($ million)
• 5.5 Geography segment analysis 2020 - 2024
  • Historic Market Size - Geography Segment 2020 - 2024 ($ million)
• 5.6 Country segment analysis 2020 - 2024
  • Historic Market Size - Country Segment 2020 - 2024 ($ million)

6 Qualitative Analysis

• 6.1 AI Impact on Global Biosimilars Market
• 6.2 Impact of Geopolitical Conflict on Global Biosimilars Market

7 Five Forces Analysis

• 7.1 Five forces summary
  • Five forces analysis - Comparison between 2025 and 2030
• 7.2 Bargaining power of buyers
  • Bargaining power of buyers - Impact of key factors 2025 and 2030
• 7.3 Bargaining power of suppliers
  • Bargaining power of suppliers - Impact of key factors in 2025 and 2030
• 7.4 Threat of new entrants
  • Threat of new entrants - Impact of key factors in 2025 and 2030
• 7.5 Threat of substitutes
  • Threat of substitutes - Impact of key factors in 2025 and 2030
• 7.6 Threat of rivalry
  • Threat of rivalry - Impact of key factors in 2025 and 2030
• 7.7 Market condition

8 Market Segmentation by Product Type

• 8.1 Market segments
• 8.2 Comparison by Product Type
• 8.3 Monoclonal antibodies - Market size and forecast 2025-2030
• 8.4 Insulin - Market size and forecast 2025-2030
• 8.5 Human growth hormone - Market size and forecast 2025-2030
• 8.6 Others - Market size and forecast 2025-2030
• 8.7 Market opportunity by Product Type
  • Market opportunity by Product Type ($ million)

9 Market Segmentation by Application

• 9.1 Market segments
• 9.2 Comparison by Application
• 9.3 Oncology and hematology - Market size and forecast 2025-2030
• 9.4 Endocrinology - Market size and forecast 2025-2030
• 9.5 Immunology - Market size and forecast 2025-2030
• 9.6 Nephrology - Market size and forecast 2025-2030
• 9.7 Market opportunity by Application
  • Market opportunity by Application ($ million)

10 Market Segmentation by Manufacturing Type

• 10.1 Market segments
• 10.2 Comparison by Manufacturing Type
• 10.3 In-house manufacturing - Market size and forecast 2025-2030
• 10.4 Contract manufacturing - Market size and forecast 2025-2030
• 10.5 Market opportunity by Manufacturing Type
  • Market opportunity by Manufacturing Type ($ million)

11 Customer Landscape

• 11.1 Customer landscape overview
  • Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

12 Geographic Landscape

• 12.1 Geographic segmentation
• 12.2 Geographic comparison
• 12.3 North America - Market size and forecast 2025-2030
  • 12.3.1 US - Market size and forecast 2025-2030
  • 12.3.2 Canada - Market size and forecast 2025-2030
  • 12.3.3 Mexico - Market size and forecast 2025-2030
• 12.4 Europe - Market size and forecast 2025-2030
  • 12.4.1 Germany - Market size and forecast 2025-2030
  • 12.4.2 UK - Market size and forecast 2025-2030
  • 12.4.3 France - Market size and forecast 2025-2030
  • 12.4.4 Italy - Market size and forecast 2025-2030
  • 12.4.5 Spain - Market size and forecast 2025-2030
  • 12.4.6 The Netherlands - Market size and forecast 2025-2030
• 12.5 Asia - Market size and forecast 2025-2030
  • 12.5.1 China - Market size and forecast 2025-2030
  • 12.5.2 India - Market size and forecast 2025-2030
  • 12.5.3 Japan - Market size and forecast 2025-2030
  • 12.5.4 South Korea - Market size and forecast 2025-2030
  • 12.5.5 Thailand - Market size and forecast 2025-2030
  • 12.5.6 Indonesia - Market size and forecast 2025-2030
• 12.6 Rest of World (ROW) - Market size and forecast 2025-2030
  • 12.6.1 Brazil - Market size and forecast 2025-2030
  • 12.6.2 Saudi Arabia - Market size and forecast 2025-2030
  • 12.6.3 UAE - Market size and forecast 2025-2030
  • 12.6.4 Turkey - Market size and forecast 2025-2030
  • 12.6.5 Argentina - Market size and forecast 2025-2030
  • 12.6.6 South Africa - Market size and forecast 2025-2030
  • 12.6.7 Colombia - Market size and forecast 2025-2030
  • 12.6.8 Israel - Market size and forecast 2025-2030
• 12.7 Market opportunity by geography
  • Market opportunity by geography ($ million)
  • Data Tables on Market opportunity by geography ($ million)

13 Drivers, Challenges, and Opportunity

• 13.1 Market drivers
  • Increasing patent expirations and intensifying focus on cost-effectiveness
  • Rising global incidence of chronic and autoimmune diseases
  • Technological advancements in progress in biomanufacturing
• 13.2 Market challenges
  • Navigating evolving and complex regulatory frameworks
  • Intensive patent litigation and strategic obstacles
  • Overcoming physician and patient reluctance
• 13.3 Impact of drivers and challenges
  • Impact of drivers and challenges in 2025 and 2030
• 13.4 Market opportunities
  • Strategic shift towards interchangeability and pursuit of bio betters
  • Expansion into novel therapeutic areas and increased focus on emerging markets
  • Embracing vertical integration and advanced manufacturing technologies

14 Competitive Landscape

• 14.1 Overview
• 14.2 Competitive Landscape
  • Overview on criticality of inputs and factors of differentiation
• 14.3 Landscape disruption
  • Overview on factors of disruption
• 14.4 Industry risks
  • Impact of key risks on business

15 Competitive Analysis

• 15.1 Companies profiled
  • Companies covered
• 15.2 Company ranking index
  • Company ranking index
• 15.3 Market positioning of companies
  • Matrix on companies position and classification
• 15.4 Abbott Laboratories
  • Abbott Laboratories - Overview
  • Abbott Laboratories - Business segments
  • Abbott Laboratories - Key news
  • Abbott Laboratories - Key offerings
  • Abbott Laboratories - Segment focus
  • SWOT
• 15.5 Biocon Ltd.
  • Biocon Ltd. - Overview
  • Biocon Ltd. - Business segments
  • Biocon Ltd. - Key offerings
  • Biocon Ltd. - Segment focus
  • SWOT
• 15.6 Dr. Reddys Laboratories Ltd.
  • Dr. Reddys Laboratories Ltd. - Overview
  • Dr. Reddys Laboratories Ltd. - Business segments
  • Dr. Reddys Laboratories Ltd. - Key news
  • Dr. Reddys Laboratories Ltd. - Key offerings
  • Dr. Reddys Laboratories Ltd. - Segment focus
  • SWOT
• 15.7 Fresenius Kabi AG
  • Fresenius Kabi AG - Overview
  • Fresenius Kabi AG - Product / Service
  • Fresenius Kabi AG - Key offerings
  • SWOT
• 15.8 Intas Pharmaceuticals Ltd.
  • Intas Pharmaceuticals Ltd. - Overview
  • Intas Pharmaceuticals Ltd. - Product / Service
  • Intas Pharmaceuticals Ltd. - Key offerings
  • SWOT
• 15.9 NeuClone Pty Ltd.
  • NeuClone Pty Ltd. - Overview
  • NeuClone Pty Ltd. - Product / Service
  • NeuClone Pty Ltd. - Key offerings
  • SWOT
• 15.10 Organon and Co.
  • Organon and Co. - Overview
  • Organon and Co. - Product / Service
  • Organon and Co. - Key offerings
  • SWOT
• 15.11 Pfizer Inc.
  • Pfizer Inc. - Overview
  • Pfizer Inc. - Business segments
  • Pfizer Inc. - Key news
  • Pfizer Inc. - Key offerings
  • Pfizer Inc. - Segment focus
  • SWOT
• 15.12 Reliance Life Sciences Pvt. Ltd.
  • Reliance Life Sciences Pvt. Ltd. - Overview
  • Reliance Life Sciences Pvt. Ltd. - Product / Service
  • Reliance Life Sciences Pvt. Ltd. - Key offerings
  • SWOT
• 15.13 Sandoz Group AG
  • Sandoz Group AG - Overview
  • Sandoz Group AG - Business segments
  • Sandoz Group AG - Key news
  • Sandoz Group AG - Key offerings
  • Sandoz Group AG - Segment focus
  • SWOT
• 15.14 STADA Arzneimittel AG
  • STADA Arzneimittel AG - Overview
  • STADA Arzneimittel AG - Business segments
  • STADA Arzneimittel AG - Key offerings
  • STADA Arzneimittel AG - Segment focus
  • SWOT
• 15.15 Teva Pharmaceutical Ltd.
  • Teva Pharmaceutical Ltd. - Overview
  • Teva Pharmaceutical Ltd. - Business segments
  • Teva Pharmaceutical Ltd. - Key news
  • Teva Pharmaceutical Ltd. - Key offerings
  • Teva Pharmaceutical Ltd. - Segment focus
  • SWOT
• 15.16 Viatris Inc.
  • Viatris Inc. - Overview
  • Viatris Inc. - Business segments
  • Viatris Inc. - Key news
  • Viatris Inc. - Key offerings
  • Viatris Inc. - Segment focus
  • SWOT
• 15.17 Zentiva Group
  • Zentiva Group - Overview
  • Zentiva Group - Product / Service
  • Zentiva Group - Key offerings
  • SWOT
• 15.18 Zydus Lifesciences Ltd.
  • Zydus Lifesciences Ltd. - Overview
  • Zydus Lifesciences Ltd. - Business segments
  • Zydus Lifesciences Ltd. - Key news
  • Zydus Lifesciences Ltd. - Key offerings
  • Zydus Lifesciences Ltd. - Segment focus
  • SWOT

16 Appendix

• 16.1 Scope of the report
  • Market definition
  • Objectives
  • Notes and caveats
• 16.2 Inclusions and exclusions checklist
  • Inclusions checklist
  • Exclusions checklist
• 16.3 Currency conversion rates for US$
  • Currency conversion rates for US$
• 16.4 Research methodology
  • Research methodology
• 16.5 Data procurement
  • Information sources
• 16.6 Data validation
  • Data validation
• 16.7 Validation techniques employed for market sizing
  • Validation techniques employed for market sizing
• 16.8 Data synthesis
  • Data synthesis
• 16.9 360 degree market analysis
  • 360 degree market analysis
• 16.10 List of abbreviations
  • List of abbreviations